Skip to content
Companies

Consano Bio

Biologic therapies for orthopedic injuries

Raised to date

$51.7M

of $65.7M offered across 2 Form D filings

Still open
$14M
Investors
18
Last filed
Mar 20, 2026

About

Consano Bio is an early-stage biotechnology startup founded in 2022 and headquartered in Des Moines, Iowa. The company focuses on developing first-in-category biologic therapeutics to treat painful and debilitating orthopedic conditions. Its core strategy is to target the underlying drivers of disease rather than merely addressing symptoms.

The company's approach is designed to create a healing microenvironment at the injury site by shifting it to an anti-inflammatory state, establishing a new protein matrix, and promoting local cell proliferation to facilitate natural repair.

Funding

$48.9M round, first sold Mar 2026$34.8M sold$14M still open20252026
Now
  • EquityFiled Mar 20, 2026Form D
    $34.8M/ $48.9M
  • Security to be acquiredFiled Dec 12, 2025Form D
    $16.8M/ $16.8M

Product

C-1101

Biologic Therapeutic

C-1101 is an allogenic, multi-protein therapeutic currently in development. It is engineered to treat orthopedic injuries by modulating the local environment to favor healing and tissue regeneration.

  • Utilizes potent cytokines to shift the microenvironment from a pro-inflammatory to an anti-inflammatory state.
  • Establishes a protein matrix to provide a scaffold for local cell proliferation.
  • Leverages platelet growth factors to stimulate healing processes directly at the site of injury.

Built for

The future primary customers will be healthcare providers, such as orthopedic surgeons and sports medicine specialists, who treat patients with significant orthopedic conditions.

People on file